Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5787675 | 1.00 | FFAR1 (0.51) | FFAR1HPGDALDH1A1RAB9ACYP3A4 | |
| SCHEMBL5785245 | 1.00 | FFAR1 (0.51) | FFAR1HPGDALDH1A1RAB9ACYP3A4 | |
| SCHEMBL21237722 | 0.89 | PTGS2 (0.55) | FFAR1CYP2C19 | |
| SCHEMBL21237726 | 0.89 | PTGS2 (0.55) | FFAR1CYP2C19 | |
| SCHEMBL11142933 | 0.84 | FFAR1 (0.49) | FFAR1HPGDALDH1A1RAB9ACYP3A4 | |
| SCHEMBL237090 | 0.83 | FFAR1 (0.70) | FFAR1HPGDALDH1A1RAB9ACYP3A4 | |
| SCHEMBL7398650 | 0.83 | ACHE (0.60) | FFAR1HPGDALDH1A1RAB9ACYP3A4 | |
| SCHEMBL237091 | 0.83 | FFAR1 (0.70) | FFAR1HPGDALDH1A1RAB9ACYP3A4 | |
| SCHEMBL11399936 | 0.83 | ACHE (0.60) | FFAR1HPGDALDH1A1RAB9ACYP3A4 | |
| SCHEMBL1149768 | 0.83 | FFAR1 (0.70) | FFAR1HPGDALDH1A1RAB9ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150349-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| EP-3681885-B1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3681885-B1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220169647-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| US-20220169647-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| US-11292791-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-11292791-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| EP-0079049-B1 | NOVEL SUBSTITUTED ALKANOYLIMIDAZOL-2-ONE DERIVATIVES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-04-01 | — | — | EP | disclosed |
| US-4447619-A | CARDIOTONIC AGENTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1984-05-08 | — | — | US | disclosed |
| EP-0079049-A2 | Novel substituted alkanoylimidazol-2-one derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1983-05-18 | — | — | EP | disclosed |
| US-4367236-A | CARDIOTONIC AGENTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1983-01-04 | — | — | US | disclosed |
| US-4198519-A | Anti-inflammatory compounds | BEECHAM GROUP LIMITED (GB) | 1980-04-15 | — | — | US | disclosed |
| US-4192883-A | ANTITUSSIVES | PIERRE FABRE, S.A. (FR) | 1980-03-11 | — | — | US | disclosed |
| US-4153718-A | Anti-inflammatory compounds | BEECHAM GROUP LIMITED (GB) | 1979-05-08 | — | — | US | disclosed |
| US-4122199-A | Amides of pyrrolidinoethylamine which can be used in treatment of coughs | PIERRE FABRE S.A. (FR) | 1978-10-24 | — | — | US | disclosed |
| US-4113680-A | Method for preparing 17 α-ester-21-halo pregnanes | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1978-09-12 | — | — | US | disclosed |
| US-3992396-A | TRANQUILIZERS, HYPNOTICS | SANDOZ, INC. (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292791-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | EP300, CREBBP, BRD3 | FFAR1 3803/4885HPGD 2119/4885ALDH1A1 3405/4885 |
| US-20240150349-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | EP300, CREBBP, BRD3 | FFAR1 3803/4885HPGD 2119/4885ALDH1A1 3405/4885 |
| US-20220169647-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | EP300, CREBBP, BRD3 | FFAR1 3803/4885HPGD 2119/4885ALDH1A1 3405/4885 |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | EP300, CREBBP, BRD3 | FFAR1 3803/4885HPGD 2119/4885ALDH1A1 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.